Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00568035 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of QR-333 in Patient's With Symptomatic Diabetic Neuropathy
A Phase 2 study of Diabetic Neuropathy, sponsored by Quigley Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
- 19
- Study locations
NCT00568035 is a Phase 2 study of Diabetic Neuropathy that has completed, run by Quigley Pharma. The registered enrollment target is 140 participants, below the 167-participant average among 8 other Diabetic Neuropathy trials with a reported enrollment target (16% lower). The trial reports 19 study locations across 10 states.
The verdict
NCT00568035, a Phase 2 study of Diabetic Neuropathy, has completed, sponsored by Quigley Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
- 19
- Study locations
Study Summary
The purpose of this study is to determine whether QR-333 is safe and effective in the treatment of diabetic neuropathy as compared to placebo.
Conditions Studied
Interventions
- DRUG QR-333
Study Locations (19)
Florida
- Renstar Medical Research - Ocala
- Baptist Clinical Research - Pensacola
- Stedman Clinical Trails - Tampa
- Metabolic Research Institute, Inc. - West Palm Beach
California
- Pacific Sleep Medicine Services, Inc - Fountain Valley
- Advanced Medical Research, LLC - Lakewood
- Diablo Clinical Research, Inc. - Walnut Creek
Texas
- UT Southwestern Medical Center at Dallas - Dallas
- dgd Research - San Antonio
- Endeavor Clinical Trials, PA - San Antonio
Alabama
- Parkway Medical Center - Birmingham
- Seale Harris Clinic / Alliance Clinical Research - Birmingham
New Jersey
- Rwjms/Umdnj - New Brunswick
- Land Clinical Studies - West Caldwell
Missouri
- A&A Pain Institute - St Louis
New York
- Kaleida Health, Diabetes Center of WNY - Buffalo
North Carolina
- ECU Diabetes Research Center, Brody School of Medicine - Greenville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2006-12 |
| Est. Completion | 2008-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00568035
The ClinicalTrials.gov registry entry for NCT00568035 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 167-participant average among 8 other Diabetic Neuropathy trials with a reported enrollment target (16% lower). The listed sponsor is Quigley Pharma, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Neuropathy appearing as the primary indexed condition, and to 1 intervention - of which QR-333 is the first listed.
NCT00568035 reports 19 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, Texas.
Frequently Asked Questions
What is clinical trial NCT00568035 about?
NCT00568035 is a clinical study titled "Safety and Efficacy Study of QR-333 in Patient's With Symptomatic Diabetic Neuropathy". The purpose of this study is to determine whether QR-333 is safe and effective in the treatment of diabetic neuropathy as compared to placebo.
What is the current status of trial NCT00568035?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2006-12. Estimated completion is 2008-11.
What conditions does trial NCT00568035 study?
This clinical trial studies the following conditions: Diabetic Neuropathy.
What interventions are being tested in trial NCT00568035?
The interventions under investigation include: QR-333 (DRUG).
Who is sponsoring clinical trial NCT00568035?
This trial is sponsored by Quigley Pharma, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00568035 being conducted?
This trial has 19 study locations across Alabama, California, Florida, Missouri, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Neuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of DA-9801 to Treat Diabetic Neuropathy
COMPLETED · Phase 2
-
The Efficacy and Safety of Clonidine Hydrochloride Topical Gel, vs Clonidine Hydrochloride Gel Comparator to Treat Painful Diabetic Neuropathy
COMPLETED · Phase 2
-
The Effect of Ruboxistaurin on Small Fiber Function
COMPLETED · Phase 2
-
Clinical Outcomes Related to Treatment of Distal Symmetric Polyneuropathy Using Semiconductor Embedded Therapeutic Socks
RECRUITING · NA
-
Long COVID-19 Cutaneous Signatures: An ARPA Funded Research Project
ACTIVE NOT RECRUITING
-
Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.